Alexandra Léary
YOU?
Author Swipe
View article: Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
TP53 mutations characteristics among t-MN PARPi national cohort.
View article: Supplementary Table S3 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
Supplementary Table S3 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer Open
Clinical characteristics according to BRCA status
View article: Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Blood smear and bone marrow aspiration of patient referred for cytopenia post PARPi.
View article: Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer Open
Clinical data and outcomes of patients included
View article: Supplementary Table S1 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
Supplementary Table S1 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer Open
Primer sequences for methylation analysis (methylation-specific ddPCR)
View article: Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience Open
Patient characteristics of the national cohort according to the type of PARPi received (olaparib vs. other PARP inhibitors).
View article: Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer Open
PURPOSE In patients with ovarian cancer undergoing neoadjuvant chemotherapy (NACT) with the goal of achieving complete interval cytoreductive surgery (ICS), tools are needed to accurately assess NACT efficacy and predict the feasibility of…
View article: 80 Composite score combining collagen density and spatial organization predicts immune checkpoint inhibitor resistance in mismatch repair-deficient endometrial cancer
80 Composite score combining collagen density and spatial organization predicts immune checkpoint inhibitor resistance in mismatch repair-deficient endometrial cancer Open
View article: The extracellular matrix dictates ovarian cancer cell migration in an in vivo-derived circulating environment
The extracellular matrix dictates ovarian cancer cell migration in an in vivo-derived circulating environment Open
Ovarian cancer (OC) disseminates via ascites and interaction with peritoneal extracellular matrix (ECM). To dissect the crosstalk between ECM and ascites in OC cell migration, we developed an ovarian tumor-on-chip integrating OC tumor sphe…
View article: Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial Open
View article: Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Open
View article: Supplementary Table 8 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Table 8 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
Individual AT83 mouse tumor volumes during EX-527 treatment.
View article: Supplementary Table 3 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Table 3 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
list of primers used for qPCR on human (KGN, COV434) and mouse (AT29 cells) GCT cell lines
View article: Supplementary Table 1 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Table 1 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
Bulk RNA-seq data with markers of granulosa cells
View article: Supplementary Figure 2 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Figure 2 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
PCA analyses of RNA-seq
View article: Supplementary Table 7 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Table 7 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
Nrf2 target genes and ferroptosis-related genes in the three cell lines.
View article: Supplementary Figure 1 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Figure 1 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
study of SIRT1 expression
View article: Supplementary Table 6 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Table 6 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
Genes of the MitoCarta3.0 database altered by EX-527 treatment in the three cell lines.
View article: Supplementary Table 2 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Table 2 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
List of antibodies used for immunohistochemistry and Western blot
View article: Supplementary Table 5 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Table 5 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
RNA-seq data showing DEGs in the three cell lines
View article: Data from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Data from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
Clinical management of patients with ovarian granulosa cell tumor (GCT) remains poor. Sirtuin-1 (SIRT1), a deacetylase enzyme involved in the regulation of tumor growth and metastasis, may represent a therapeutic target because of the avai…
View article: Supplementary Figure 4 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Figure 4 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
RT-qPCR analyses of selected DEGs identified by RNA-seq
View article: Supplementary Figure 3 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Figure 3 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
Dot plots of GO-BP
View article: Supplementary Table 4 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
Supplementary Table 4 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways Open
Total number of genes expressed and differential gene expression in AT29, COV434 and KGN cells
View article: Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation Open
PURPOSE Patients with platinum-resistant/platinum-refractory high-grade serous ovarian cancer (HGSOC) without a BRCA mutation have poor prognosis and limited treatment options. We report efficacy and biomarker data from EPIK-O, which inves…
View article: Prognostic Value of a Joint K‐PD Model With Tumor Size Dynamics and CA‐125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study
Prognostic Value of a Joint K‐PD Model With Tumor Size Dynamics and CA‐125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study Open
In patients with recurrent advanced ovarian cancer, there is a need for companion tests to guide the development of innovative chemotherapy‐free treatments. The modeled longitudinal CA‐125 ELIMination rate constant K KELIM‐B was a major pr…
View article: Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders Open
Supplementary Figures
View article: Data from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
Data from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders Open
Purpose:PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to…
View article: Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders
Supplementary Data 1 from Clonal Evolution of <i>PPM1D</i> Mutations in the Spectrum of Myeloid Disorders Open
Supplementary Tables
View article: Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors Open
The trial is registered at ClinicalTrials.gov, NCT04008797.